Novartis eyes double blockbuster potential for Genmab-developed drug
Sclerosis treatment Kesimpta, which was developed by Genmab, could surpass USD 2bn in revenue in the future, says the company selling the drug, Novartis.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
Sclerosis treatment Kesimpta (ofatumumab) will surpass annual sales of USD 2bn over the coming years, said Novartis, the company marketing the drug, on Thursday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
